Gujarat Kidney & Super Speciality IPO Review 2025: Dates, Price, Financials, GMP, and Recommendation

The Gujarat Kidney & Super Speciality IPO is among the notable healthcare IPOs of December 2025. The company operates a network of multi-speciality hospitals in Gujarat with a strong focus on kidney care, urology, and tertiary medical services. With rising demand for quality healthcare and regional hospital expansion, this IPO has attracted attention from retail and long-term investors alike.

Below is a complete breakdown of the IPO details, company fundamentals, financials, and a clear recommendation on whether investors should subscribe.

Gujarat Kidney & Super Speciality IPO Details

Particulars	Details
IPO Opening Date	22 December 2025
IPO Closing Date	24 December 2025
IPO Allotment Date	26 December 2025
IPO Listing Date	30 December 2025
IPO Price Band	₹108 – ₹114 per share
Lot Size	128 shares
Minimum Investment for Retail Investors	₹14,592 (1 lot at upper price band)
Maximum Retail Investment Cap	Up to ₹2 lakh (approx. 13 lots)
Total Fund Raise	Approximately ₹250.80 crore

About Gujarat Kidney & Super Speciality

Gujarat Kidney & Super Speciality Limited is a Gujarat-based healthcare company operating a chain of multi-speciality hospitals with a strong presence in nephrology and urology care. The company primarily serves patients in Tier-2 and Tier-3 cities, addressing the growing need for affordable and specialized medical services.

The hospital network offers a mix of secondary and tertiary care services, including diagnostics, surgeries, dialysis, critical care, and pharmacy operations. IPO proceeds will be used for hospital expansion, acquisition of new facilities, advanced medical equipment, repayment of borrowings, and general corporate purposes.

Key Management

The company is led by an experienced medical and professional management team with deep operational knowledge of hospital administration and healthcare services. The promoters and senior management have played a key role in expanding the hospital footprint across Gujarat and improving operational efficiency.

(Investors are advised to review the Red Herring Prospectus for detailed promoter and related-party information.)

Major Services

Gujarat Kidney & Super Speciality offers a wide range of healthcare services, including:

• Nephrology and dialysis services
• Urology and kidney transplant-related treatments
• Multi-speciality inpatient and outpatient care
• Diagnostic and pathology services
• In-house hospital pharmacy operations
• Critical care and surgical procedures

The company focuses on high-occupancy specialties that ensure steady patient inflow and recurring revenues.

Financials / Revenue Performance

The company has shown sharp improvement in financial performance, albeit from a relatively small base.

Financial Year	Total Revenue (₹ Cr)	Profit After Tax (₹ Cr)
FY23	~3.0	~0.6
FY24	~5.5	~1.7
FY25	~40.4	~9.5

Key Financial Highlights

• Strong revenue jump in FY25 driven by expansion and higher hospital utilization
• Significant improvement in profitability
• Healthcare services provide relatively stable demand compared to cyclical sectors
• Growth is rapid but still at an early stage, indicating higher execution risk

Competitors

Gujarat Kidney & Super Speciality operates in a competitive healthcare environment. Key competitors include:

• Shalby Hospitals
• Sterling Hospitals
• Regional multi-speciality hospitals in Gujarat
• Large national chains such as Apollo Hospitals and Fortis (indirect competition)

While large hospital chains dominate metros, regional players benefit from local trust, lower operating costs, and growing demand in non-metro cities.

Conclusion

The Gujarat Kidney & Super Speciality IPO represents a growth-focused healthcare play with exposure to India’s expanding hospital sector. The company has shown strong recent financial growth and operates in a structurally growing industry driven by lifestyle diseases, aging population, and increased healthcare access.

However, the company is still relatively small, and its rapid growth comes with execution, expansion, and regulatory risks. Valuations and long-term performance will depend on how efficiently the company scales operations and maintains margins.

Recommendation: Apply or Avoid?

Recommendation: Apply with Caution (Long-Term Perspective)

Reasons to Apply:

• Strong revenue and profit growth in recent years
• Presence in a high-demand healthcare segment (kidney and speciality care)
• Expansion plans using IPO proceeds
• Structural long-term growth in Indian healthcare sector

Points to Consider:

• Growth is from a low base, increasing volatility
• Hospital business is capital-intensive
• Limited short-term listing gain visibility
• Retail quota is relatively small

Final Verdict:

The Gujarat Kidney & Super Speciality IPO is better suited for long-term investors with moderate risk appetite who are looking to gain exposure to the regional healthcare space. Short-term or listing-gain-focused investors should remain cautious and track GMP and market sentiment closer to listing.